Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Hepatitis C

  Free Subscription


Articles published in J Med Virol

Retrieve available abstracts of 100 articles:
HTML format
Text format



Single Articles


    November 2018
  1. KHAN AJ, Saraswat VA, Ranjan P, Parmar D, et al
    Polymorphism in IFNL3/IL28B gene and risk to non-cirrhotic chronic hepatitis C genotype 3 virus infection and its effect on the response to combined daclatasvir and sofosbuvir therapy.
    J Med Virol. 2018 Nov 15. doi: 10.1002/jmv.25359.
    PubMed     Text format     Abstract available


  2. NAGAOKI Y, Imamura M, Nisihda Y, Daijo K, et al
    The impact of interferon-free direct-acting antivirals on clinical outcome after curative treatment for hepatitis C virus-associated hepatocellular carcinoma; comparison with interferon-based therapy.
    J Med Virol. 2018 Nov 1. doi: 10.1002/jmv.25352.
    PubMed     Text format     Abstract available


  3. DA COSTA MARQUES BORGES LF, Zalis MG, Santoro-Lopes G, Varella RB, et al
    Hepatitis C virus (HCV) genotypes in hemodialysis patients in Angola.
    J Med Virol. 2018 Nov 1. doi: 10.1002/jmv.25354.
    PubMed     Text format     Abstract available


    September 2018
  4. EL HADI H, Benani A, Qmichou Z, Lazar F, et al
    Development and Validation of an RT-qPCR Assay for Rapid Detection and Quantification of Hepatitis C Virus RNA for Routine Testing in Moroccan Clinical Specimens.
    J Med Virol. 2018 Sep 29. doi: 10.1002/jmv.25326.
    PubMed     Text format     Abstract available


  5. WAHID B, Waqar M, Rasool N, Wasim M, et al
    Prevalence of TSH dysfunction among sofosbuvir-treated HCV infected patients: a real-world clinical experience.
    J Med Virol. 2018 Sep 19. doi: 10.1002/jmv.25319.
    PubMed     Text format     Abstract available


  6. PENG H, Zhang L, Feng Y, Tang H, et al
    A cross-sectional serum investigation of a clustering HCV infection in Southwest China.
    J Med Virol. 2018 Sep 11. doi: 10.1002/jmv.25315.
    PubMed     Text format     Abstract available


  7. KHOSRAVI A, Karimi-Sari H, Abedi-Andani M, Behnava B, et al
    Acute Changes in Cardiac Function by Direct-acting Antiviral Therapy for Hepatitis C Infected Thalassemia Patients.
    J Med Virol. 2018 Sep 11. doi: 10.1002/jmv.25314.
    PubMed     Text format     Abstract available


  8. GUOPING D, Xiaoshan L, Musa TH, Yu J, et al
    The Nationwide Distribution and Trends of Hepatitis C Virus Genotypes in Mainland China.
    J Med Virol. 2018 Sep 7. doi: 10.1002/jmv.25311.
    PubMed     Text format     Abstract available


  9. SASAKI R, Meyer K, Moriyama M, Kato N, et al
    Rapid hepatitis C virus clearance by antivirals correlates with immune status of infected patients.
    J Med Virol. 2018 Sep 7. doi: 10.1002/jmv.25310.
    PubMed     Text format     Abstract available


  10. LI Y, Zeng Y, Zeng G, Li J, et al
    The Effects of Direct-Acting Antiviral Agents on the Frequency of Myeloid-Derived Suppressor Cells and Natural Killer Cells in Patients with Chronic Hepatitis C.
    J Med Virol. 2018 Sep 1. doi: 10.1002/jmv.25302.
    PubMed     Text format     Abstract available


    August 2018
  11. ELBAZ T, Abdo M, Omar H, Hassan EA, et al
    Efficacy and safety of sofosbuvir and daclatasvir with or without ribavirin in elderly patients with chronic hepatitis C virus infection.
    J Med Virol. 2018 Aug 23. doi: 10.1002/jmv.25287.
    PubMed     Text format     Abstract available


  12. JORDIER F, Deligny ML, Barre R, Robert C, et al
    Human pegivirus (HPgV) isolates characterized by deep sequencing from HCV- and HIV-RNA positive blood donations, France.
    J Med Virol. 2018 Aug 22. doi: 10.1002/jmv.25290.
    PubMed     Text format     Abstract available


  13. EL-HEFNY MA, Fouad SA, Hussein TD, Abdel-Hameed R, et al
    Circulating miRNAs as predictive biomarkers for liver disease progression of chronic hepatitis C (genotype-4) Egyptian patients.
    J Med Virol. 2018 Aug 22. doi: 10.1002/jmv.25294.
    PubMed     Text format     Abstract available


  14. AKUTA N, Sezaki H, Suzuki F, Fujiyama S, et al
    Favorable efficacy of glecaprevir plus pibrentasvir as salvage therapy for HCV failures to prior direct-acting antivirals regimens.
    J Med Virol. 2018 Aug 9. doi: 10.1002/jmv.25278.
    PubMed     Text format     Abstract available


  15. KAHYESH-ESFANDIARY R, Sadigh ZA, Esghaei M, Bastani MN, et al
    Detection of HCV Genome in Peripheral Blood Mononuclear Cells of Iranian Seropositive and HCV RNA negative in Plasma of Patients with Beta-thalassemia Major: Occult HCV Infection.
    J Med Virol. 2018 Aug 9. doi: 10.1002/jmv.25279.
    PubMed     Text format     Abstract available


  16. LU T, Han Y, Zhang R, Zhang K, et al
    Quantitative detection of hepatitis C virus RNA in urine of patients with chronic hepatitis C using a novel real-time PCR assay.
    J Med Virol. 2018 Aug 9. doi: 10.1002/jmv.25280.
    PubMed     Text format     Abstract available


  17. PRAKASH S, Shukla S, Ramakrishna V, Jain A, et al
    Distribution of Hepatitis C Genotypes in Uttar Pradesh, India; Rare Genotype 4 Detected.
    J Med Virol. 2018 Aug 7. doi: 10.1002/jmv.25277.
    PubMed     Text format     Abstract available


    July 2018
  18. MORIO K, Imamura M, Kawakami Y, Nakamura Y, et al
    Advanced liver fibrosis effects on the response to sofosbuvir-based antiviral therapies for chronic hepatitis C.
    J Med Virol. 2018 Jul 17. doi: 10.1002/jmv.25267.
    PubMed     Text format     Abstract available


  19. HASHEM M, Zaghla H, Zakaria Z, Allam WR, et al
    High spontaneous clearance of symptomatic iatrogenic acute hepatitis C genotype 4 infection.
    J Med Virol. 2018 Jul 16. doi: 10.1002/jmv.25270.
    PubMed     Text format     Abstract available


  20. ZHAO N, Zheng W, Wu D, Wang X, et al
    Clinical value of HCcAg levels in monitoring acute hepatitis C spontaneous clearance or treatment-induced clearance.
    J Med Virol. 2018 Jul 11. doi: 10.1002/jmv.25256.
    PubMed     Text format     Abstract available


  21. JOGEDA EL, Avi R, Pauskar M, Kallas E, et al
    Association of IFNlambda4 rs12979860 Polymorphism with the Acquisition of HCV and HIV Infections among People Who Inject Drugs.
    J Med Virol. 2018 Jul 10. doi: 10.1002/jmv.25258.
    PubMed     Text format     Abstract available


  22. EL BATAE H, Amer I, Kobtan A, Saied SM, et al
    Seroprevalence of hepatitis C virus among the newcomer students, Kafrelsheikh University, Egypt.
    J Med Virol. 2018 Jul 7. doi: 10.1002/jmv.25249.
    PubMed     Text format     Abstract available


    June 2018
  23. DEGEFA B, Gebreeyesus T, Gebremedhin Z, Melkamu G, et al
    Prevalence of hepatitis B virus, hepatitis C virus and human immunodeficiency virus among blood donors of Mekelle blood bank, Northern Ethiopia: A three year retrospective study.
    J Med Virol. 2018 Jun 15. doi: 10.1002/jmv.25248.
    PubMed     Text format     Abstract available


  24. WAKED I, Esmat G, Fouad R, Allam N, et al
    Change in hepatic profile in hepatitis C virus genotype 4 patients with compensated cirrhosis receiving ombitasvir, paritaprevir, and ritonavir plus ribavirin: a subanalysis of the AGATE-II study.
    J Med Virol. 2018 Jun 13. doi: 10.1002/jmv.25243.
    PubMed     Text format     Abstract available


    May 2018
  25. MARYAM M, Idrees M
    Study of promoter hypomethylation profiles of RAS oncogenes in Hepatocellular Carcinoma derived from Hepatitis C virus genotype 3a in Pakistani population.
    J Med Virol. 2018 May 9. doi: 10.1002/jmv.25221.
    PubMed     Text format     Abstract available


  26. ALEM SA, Said M, Anwar I, Abdellatif Z, et al
    Improvement of LSM, ARFI measurements and non-invasive fibrosis markers after DAAs for HCV G4 recurrence post living donor liver transplantation: Egyptian cohort.
    J Med Virol. 2018 May 2. doi: 10.1002/jmv.25210.
    PubMed     Text format     Abstract available


  27. DE DIEU LONGO J, Bouassa RM, Simaleko MM, Kouabosso A, et al
    Usefulness of simultaneous screening for HIV- and HCV- specific antibodies and HBsAg by capillary-based multiplex rapid diagnostic test to strengthen linkage-to-care in sub-Saharan patients attending sexually transmitted infections clinic.
    J Med Virol. 2018 May 2. doi: 10.1002/jmv.25209.
    PubMed     Text format     Abstract available


    April 2018
  28. Z M, H K, E M, N B, et al
    Indeterminate genotypes of hepatitis C virus by the Abbott RealTime HCV Genotype II assay in Morocco. About 8 cases resolved by a sequencing method.
    J Med Virol. 2018 Apr 16. doi: 10.1002/jmv.25191.
    PubMed     Text format     Abstract available


  29. VISCO-COMANDINI U, Lapa D, Lionetti R, Taibi C, et al
    Significance of detectable HCV RNA below the limit of quantification in patients treated with DAAs using standard and ultrasensitive protocols.
    J Med Virol. 2018 Apr 3. doi: 10.1002/jmv.25084.
    PubMed     Text format     Abstract available


  30. YANG R, Gao N, Chang Q, Meng X, et al
    The role of IDO, IL-10 and TGF-beta in the HCV-associated chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma.
    J Med Virol. 2018 Apr 3. doi: 10.1002/jmv.25083.
    PubMed     Text format     Abstract available


    March 2018
  31. DENG H, Deng X, Liu Y, Xu Y, et al
    Naturally occurring antiviral drug resistance in HIV patients who are mono-infected or co-infected with HBV or HCV in China.
    J Med Virol. 2018 Mar 24. doi: 10.1002/jmv.25078.
    PubMed     Text format     Abstract available


  32. ANTONIO UL, Alicia OM, Antonio MJ, Elena GM, et al
    Presence of rare hepatitis C virus subtypes, 2j, 2k and 2r, in Mexico City as identified by sequencing.
    J Med Virol. 2018 Mar 6. doi: 10.1002/jmv.25070.
    PubMed     Text format     Abstract available


    February 2018
  33. CORDIE A, Salama A, El-Sharkawy M, El-Nahaas SM, et al
    Comparing the efficiency of Fib-4, Egy-score, APRI and GUCI in liver fibrosis staging in Egyptians with chronic hepatitis C.
    J Med Virol. 2018 Feb 24. doi: 10.1002/jmv.25064.
    PubMed     Text format     Abstract available


  34. SHOUSHA HI, Abdelaziz RA, Azab SM, Khairy M, et al
    Effect of Treatment with Direct Acting Antivirals on Body Mass Index and Hepatic Steatosis in Chronic Hepatitis C.
    J Med Virol. 2018 Feb 22. doi: 10.1002/jmv.25062.
    PubMed     Text format     Abstract available


  35. RAN M, Huang J, Liang H, Jiang J, et al
    Alcohol attenuates anti-HCV function of IFN-lambda1 through up-regulation of PLASy expression in human hepatic cells.
    J Med Virol. 2018 Feb 15. doi: 10.1002/jmv.25053.
    PubMed     Text format     Abstract available


  36. OGATA F, Akuta N, Kobayashi M, Fujiyama S, et al
    Amino Acid Substitutions in the Hepatitis C Virus Core Region Predict Hepatocarcinogenesis Following Eradication of HCV RNA by All-Oral Direct-Acting Antiviral Regimens.
    J Med Virol. 2018 Feb 10. doi: 10.1002/jmv.25047.
    PubMed     Text format     Abstract available


  37. GRANDAL M, Pernas B, Tabernilla A, Marino A, et al
    Prevalence of NS5A Resistance Associated Substitutions in patients with hepatitis C virus genotypes 1a and 3: Impact on Current Therapeutic Strategies.
    J Med Virol. 2018 Feb 10. doi: 10.1002/jmv.25048.
    PubMed     Text format     Abstract available


    January 2018
  38. SUN LJ, Yu JW, Shi YG, Zhang XY, et al
    Hepatitis C virus core protein induces dysfunction of liver sinusoidal endothelial cell by down-regulation of silent information regulator 1.
    J Med Virol. 2018 Jan 19. doi: 10.1002/jmv.25034.
    PubMed     Text format     Abstract available


  39. MOUREZ T, Decroos A, Goria O, Montialoux H, et al
    Misidentification of recombinant hepatitis C virus leading to treatment failure with direct acting antivirals.
    J Med Virol. 2018 Jan 19. doi: 10.1002/jmv.25035.
    PubMed     Text format     Abstract available


  40. MARCIANO S, Haddad L, Reggiardo MV, Peralta M, et al
    Effectiveness and safety of original and generic sofosbuvir for the treatment of chronic hepatitis C: a real world study.
    J Med Virol. 2018 Jan 19. doi: 10.1002/jmv.25033.
    PubMed     Text format     Abstract available


  41. MARIO S, Carmine M, Stefania P, Margherita M, et al
    VIROLOGICAL PATTERNS OF HCV PATIENTS WITH FAILURE TO INTERFERON-FREE REGIMENS.
    J Med Virol. 2018 Jan 9. doi: 10.1002/jmv.25022.
    PubMed     Text format     Abstract available


  42. GAMIL M, Alboraie M, El-Sayed M, Elsharkawy A, et al
    Novel scores combining AFP with non-invasive markers for prediction of liver fibrosis in chronic hepatitis C patients.
    J Med Virol. 2018 Jan 6. doi: 10.1002/jmv.25026.
    PubMed     Text format     Abstract available


  43. OHYA K, Akuta N, Suzuki F, Fujiyama S, et al
    Predictors of treatment efficacy and liver stiffness changes following therapy with Sofosbuvir plus Ribavirin in patients infected with HCV genotype 2.
    J Med Virol. 2018 Jan 5. doi: 10.1002/jmv.25023.
    PubMed     Text format     Abstract available


    December 2017
  44. MATHUR P, Emmanuel B, Sneller M, Zhang X, et al
    Recovery of Hepatitis C Specific T-cell Responses after Rituximab Therapy in Hepatitis C Mixed Cryoglobulinemic Vasculitis.
    J Med Virol. 2017 Dec 13. doi: 10.1002/jmv.25002.
    PubMed     Text format     Abstract available


    November 2017
  45. ISHIGAMI M, Hayashi K, Honda T, Kuzuya T, et al
    Daclatasvir and asunaprevir treatment in patients infected by genotype 1b of hepatitis C virus with no or subtle resistant associated substitutions (RAS) in NS5A-Y93.
    J Med Virol. 2017 Nov 7. doi: 10.1002/jmv.24978.
    PubMed     Text format     Abstract available


  46. SU S, Fairley CK, Sasadeusz J, He J, et al
    HBV, HCV, and HBV/HCV co-infection among HIV-positive patients in Hunan province, China: regimen selection, hepatotoxicity, and antiretroviral therapy outcome.
    J Med Virol. 2017 Nov 1. doi: 10.1002/jmv.24988.
    PubMed     Text format     Abstract available


    October 2017
  47. GEWAID H, Mesalam AA, Ibrahim AA, Abdel Shafy DN, et al
    Establishment of a platform for molecular and immunological characterization of the RNA-dependent-RNA-polymerase NS5B of an Egyptian HCV isolate.
    J Med Virol. 2017 Oct 24. doi: 10.1002/jmv.24977.
    PubMed     Text format     Abstract available


  48. SILVA RAD, de Souza Todao J, Kamitani FL, Benedito Silva AE, et al
    MOLECULAR CHARACTERIZATION OF HEPATITIS C VIRUS IN END-STAGE RENAL DISEASE PATIENTS UNDER HEMODIALYSIS.
    J Med Virol. 2017 Oct 24. doi: 10.1002/jmv.24976.
    PubMed     Text format     Abstract available


  49. AL-RADDADI RM, Dashash NA, Alghamdi HA, Al-Raddadi ZM, et al
    Hepatitis C virus infection in Jeddah City, Saudi Arabia: Seroprevalence and knowledge.
    J Med Virol. 2017 Oct 11. doi: 10.1002/jmv.24973.
    PubMed     Text format     Abstract available


  50. CARRASCO I, Arias A, Benitez-Gutierrez L, Lledo G, et al
    Baseline NS5A Resistance Associated Substitutions May Impair DAA Response in Real-World Hepatitis C Patients.
    J Med Virol. 2017 Oct 9. doi: 10.1002/jmv.24971.
    PubMed     Text format     Abstract available


    September 2017
  51. RAHMAN M, Hossain ME, Afrad MH, Hasan R, et al
    Hepatitis C Virus infections among clients attending an HIV testing and counseling center in Dhaka, Bangladesh.
    J Med Virol. 2017 Sep 28. doi: 10.1002/jmv.24955.
    PubMed     Text format     Abstract available


  52. CIANCIO A, Bosio R, Bo S, Pellegrini M, et al
    SIGNIFICANT IMPROVEMENT OF GLYCAEMIC CONTROL IN DIABETIC PATIENTS WITH HCV INFECTION RESPONDING TO DIRECT-ACTING ANTIVIRAL AGENTS.
    J Med Virol. 2017 Sep 28. doi: 10.1002/jmv.24954.
    PubMed     Text format     Abstract available


  53. OGASAWARA N, Kobayashi M, Akuta N, Kominami Y, et al
    Serial changes in liver stiffness and controlled attenuation parameter following direct-acting antiviral therapy against hepatitis C virus genotype 1b.
    J Med Virol. 2017 Sep 14. doi: 10.1002/jmv.24950.
    PubMed     Text format     Abstract available


  54. AHMED AM, Doheim MF, Mattar OM, Sherif NA, et al
    Beclabuvir in combination with asunaprevir and daclatasvir for hepatitis C virus genotype 1 infection: A systematic review and meta-analysis.
    J Med Virol. 2017 Sep 11. doi: 10.1002/jmv.24947.
    PubMed     Text format     Abstract available


  55. CAVARETTO LDSP, Motta-Castro ARC, Teles SA, de Souza FQ, et al
    Epidemiological and molecular analysis of hepatitis B virus infection in manicurists in Central Brazil.
    J Med Virol. 2017 Sep 8. doi: 10.1002/jmv.24940.
    PubMed     Text format     Abstract available


    August 2017
  56. DEHGHANI-DEHEJ F, Sarvari J, Esghaei M, Hosseini SY, et al
    Presence of Different Hepatitis C Virus Genotypes in Plasma and Peripheral Blood Mononuclear Cell Samples of Iranian Patients with HIV Infection.
    J Med Virol. 2017 Aug 28. doi: 10.1002/jmv.24925.
    PubMed     Text format     Abstract available


  57. SHEPHERD SJ, McDonald SA, Palmateer NE, Gunson RN, et al
    HCV avidity as a tool for detection of recent HCV infection: sensitivity depends on HCV genotype.
    J Med Virol. 2017 Aug 26. doi: 10.1002/jmv.24919.
    PubMed     Text format     Abstract available


  58. SCHNELL G, Tripathi R, Krishnan P, Beyer J, et al
    Resistance Characterization of Hepatitis C Virus Genotype 2 from Japanese Patients Treated with Ombitasvir and Paritaprevir/Ritonavir.
    J Med Virol. 2017 Aug 26. doi: 10.1002/jmv.24923.
    PubMed     Text format     Abstract available


  59. MAHMUD S, Kanaani ZA, Chemaitelly H, Chaabna K, et al
    Hepatitis C Virus Genotypes in the Middle East and North Africa: Distribution, Diversity, and Patterns.
    J Med Virol. 2017 Aug 26. doi: 10.1002/jmv.24921.
    PubMed     Text format     Abstract available


  60. YANG T, Chen Q, Li D, Wang T, et al
    High prevalence of syphilis, HBV and HCV co-infection, and low rate of effective vaccination against hepatitis B in HIV-infected patients in West China hospital.
    J Med Virol. 2017 Aug 9. doi: 10.1002/jmv.24912.
    PubMed     Text format     Abstract available


    July 2017
  61. WEHMEYER MH, Ingiliz P, Christensen S, Hueppe D, et al
    Real-world effectiveness of sofosbuvir-based treatment regimens for chronic hepatitis C genotype 3 infection: results from the multicenter German hepatitis C cohort (GECCO-03).
    J Med Virol. 2017 Jul 15. doi: 10.1002/jmv.24903.
    PubMed     Text format     Abstract available


  62. LISBOA NETO G, M Malta F, Gomes-Gouvea MS, F Noble C, et al
    CHARACTERIZATION OF CLINICAL PREDICTORS OF NATURALLY OCCURRING NS3/NS4A PROTEASE POLYMORPHISM IN GENOTYPE 1 HEPATITIS C VIRUS MONO AND HIV CO-INFECTED PATIENTS.
    J Med Virol. 2017 Jul 12. doi: 10.1002/jmv.24900.
    PubMed     Text format     Abstract available


  63. LU J, Xiang X, Cao Z, Wang W, et al
    Younger trend of cirrhosis incidence in genotype 3 HCV infected patients in Eastern China.
    J Med Virol. 2017 Jul 3. doi: 10.1002/jmv.24894.
    PubMed     Text format     Abstract available


    June 2017
  64. KAN H, Imamura M, Kawakami Y, Daijo K, et al
    Emergence of drug resistance-associated variants and changes in serum lipid profiles in sofosbuvir plus ledipasvir-treated chronic hepatitis C patients.
    J Med Virol. 2017 Jun 28. doi: 10.1002/jmv.24885.
    PubMed     Text format     Abstract available


  65. MOBARAK L, Omran D, Nabeel MM, Zakaria Z, et al
    Fibro markers for prediction of hepatocellular carcinoma in Egyptian patients with chronic liver disease.
    J Med Virol. 2017;89:1062-1068.
    PubMed     Text format     Abstract available


    May 2017
  66. SHI X, Jiao B, Chen Y, Li S, et al
    MxA Is A Positive Regulator of Type I IFN Signaling in HCV Infection.
    J Med Virol. 2017 May 31. doi: 10.1002/jmv.24867.
    PubMed     Text format     Abstract available


  67. KAR P, Kumar D, Gumma PK, Chowdhury SJ, et al
    Down regulation of TRIF, TLR3 and MAVS in HCV infected liver correlates with the outcome of infection.
    J Med Virol. 2017 May 8. doi: 10.1002/jmv.24849.
    PubMed     Text format     Abstract available


  68. HUDSON B, Walker AJ, Irving WL
    Comorbidities and medications of patients with chronic hepatitis C under specialist care in the UK.
    J Med Virol. 2017 May 8. doi: 10.1002/jmv.24848.
    PubMed     Text format     Abstract available


  69. RAZIKY ME, Zayed NA, Baki AA, Mansour SA, et al
    ITPA Gene polymorphism (94C>A) Effects on Ribavirin-Induced Anemia during Therapy in Egyptian Patients with Chronic Hepatitis C.
    J Med Virol. 2017 May 8. doi: 10.1002/jmv.24844.
    PubMed     Text format     Abstract available


  70. SCOGNAMIGLIO P, Piselli P, Fusco M, Pisanti FA, et al
    DECLINING UNAWARENESS OF HCV-INFECTION PARALLEL TO DECLINING PREVALENCE IN SOUTHERN ITALY.
    J Med Virol. 2017 May 2. doi: 10.1002/jmv.24840.
    PubMed     Text format     Abstract available


    April 2017
  71. DE PASCHALE M, Manco MT, Arpino O, Ricucci V, et al
    Threshold value of LIAISON XL anti-HCV screening assay predicting positive immunoblotting results.
    J Med Virol. 2017 Apr 12. doi: 10.1002/jmv.24831.
    PubMed     Text format     Abstract available


  72. JIAO X, Fan Z, Chen H, He P, et al
    Serum and exosomal miR-122 and miR-199a as a biomarker to predict therapeutic efficacy of hepatitis C patients.
    J Med Virol. 2017 Apr 12. doi: 10.1002/jmv.24829.
    PubMed     Text format     Abstract available


    March 2017
  73. MENDIZABAL M, Haddad L, Gallardo PE, Ferrada A, et al
    Ombitasvir/paritaprevir/ritonavir/dasabuvir +/- ribavirin is safe and effective in HCV infected patients in a real-life cohort from Latin America.
    J Med Virol. 2017 Mar 29. doi: 10.1002/jmv.24816.
    PubMed     Text format     Abstract available


  74. KHALIFA RH, Labib DA, Kamel MA, Shahin RM, et al
    Role of ApoB-516C/T promoter gene polymorphism in the risk of Hepatitis C virus infection in Egyptian patients and in gender susceptibility.
    J Med Virol. 2017 Mar 29. doi: 10.1002/jmv.24815.
    PubMed     Text format     Abstract available


  75. HIRAMATSU K, Matsuda H, Nemoto T, Nosaka T, et al
    Identification of novel variants in HLA class II region related to HLA DPB1 expression and disease progression in patients with chronic hepatitis C.
    J Med Virol. 2017 Mar 22. doi: 10.1002/jmv.24814.
    PubMed     Text format     Abstract available


  76. JONES M, Cunningham ME, Wing P, DeSilva S, et al
    SB 9200, a novel agonist of innate immunity, shows potent antiviral activity against resistant HCV variants.
    J Med Virol. 2017 Mar 17. doi: 10.1002/jmv.24809.
    PubMed     Text format     Abstract available


    February 2017
  77. FLORES GL, Cruz HM, Marques VA, Villela-Nogueira CA, et al
    Performance of anti-HCV testing in dried blood spots and saliva according to HIV status.
    J Med Virol. 2017 Feb 6. doi: 10.1002/jmv.24777.
    PubMed     Text format     Abstract available


  78. WATANABE T, Tokumoto Y, Joko K, Michitaka K, et al
    Predictors of treatment efficacy and ALT non-normalization with sofosbuvir/ribavirin therapy for patients with hepatitis C virus genotype 2.
    J Med Virol. 2017 Feb 6. doi: 10.1002/jmv.24776.
    PubMed     Text format     Abstract available


    January 2017
  79. HUNDIE GB, Raj VS, Gebre Michael D, Haagmans BL, et al
    Seroepidemiology of hepatitis B and C virus infections among blood donors in Ethiopia.
    J Med Virol. 2017 Jan 25. doi: 10.1002/jmv.24770.
    PubMed     Text format     Abstract available


  80. AKUTA N, Sezaki H, Suzuki F, Fujiyama S, et al
    Ledipasvir plus sofosbuvir as salvage therapy for HCV genotype 1 failures to prior NS5A inhibitors regimens.
    J Med Virol. 2017 Jan 12. doi: 10.1002/jmv.24767.
    PubMed     Text format     Abstract available


  81. GRANDAL M, Pernas B, Marino A, Alvarez H, et al
    Characterization of chronic HCV infection in Northwest Spain: Impact of the treatment strategic plan of the Spanish National Health Service on HCV cure.
    J Med Virol. 2017 Jan 12. doi: 10.1002/jmv.24766.
    PubMed     Text format     Abstract available


    December 2016
  82. MURAKAWA M, Asahina Y, Kawai-Kitahata F, Nakagawa M, et al
    Hepatic IFNL4 expression is associated with non-response to interferon-based therapy through the regulation of basal interferon-stimulated gene expression in chronic hepatitis C patients.
    J Med Virol. 2016 Dec 30. doi: 10.1002/jmv.24763.
    PubMed     Text format     Abstract available


  83. WANG L, Chen W, WenXi, Feng J, et al
    The utility of enzyme-linked immunosorbent assays to test core antigen in the diagnosis and antiviral therapy management of hepatitis C virus infections.
    J Med Virol. 2016 Dec 13. doi: 10.1002/jmv.24754.
    PubMed     Text format     Abstract available


  84. ZHAO N, Liu J, Sun D
    Detection of HCV genotypes 1b and 2a by a reverse transcription loop-mediated isothermal amplification assay.
    J Med Virol. 2016 Dec 9. doi: 10.1002/jmv.24747.
    PubMed     Text format     Abstract available


  85. NGOC NB, Okuno Y, Ajiro M, Iida K, et al
    Retinoid derivative Tp80 exhibits anti-hepatitis C virus activity through restoration of GI-GPx expression.
    J Med Virol. 2016 Dec 6. doi: 10.1002/jmv.24739.
    PubMed     Text format     Abstract available


    November 2016
  86. ELFIKY AA, Mahdy SM, Elshemey WM
    Quantitative structure-activity relationship and molecular docking revealed a potency of anti-hepatitis C virus drugs against human corona viruses.
    J Med Virol. 2016 Nov 19. doi: 10.1002/jmv.24736.
    PubMed     Text format     Abstract available


  87. BODEAU S, Lemouel JP, Diouf M, Duverlie G, et al
    Hemoglobin during ribavirin-based HCV therapy is closely related to circulating levels of DHEA.
    J Med Virol. 2016 Nov 2. doi: 10.1002/jmv.24726.
    PubMed     Text format     Abstract available


  88. SALEMI JL, Spooner KK, Mejia de Grubb MC, Aggarwal A, et al
    National trends of hepatitis B and C during pregnancy across sociodemographic, behavioral, and clinical factors, United States, 1998-2011.
    J Med Virol. 2016 Nov 2. doi: 10.1002/jmv.24725.
    PubMed     Text format     Abstract available


    October 2016
  89. HUMAYED SM, El-Mekki AA, Mahfouz AA
    Hepatitis C virus infection in south-western Saudi Arabia: Are we still in the plateau phase?
    J Med Virol. 2016 Oct 13. doi: 10.1002/jmv.24712.
    PubMed     Text format     Abstract available


    September 2016
  90. TSUKUDA Y, Suda G, Tsunematsu S, Ito J, et al
    Anti-adipogenic and antiviral effects of L-carnitine on hepatitis C virus infection.
    J Med Virol. 2016 Sep 24. doi: 10.1002/jmv.24692.
    PubMed     Text format     Abstract available


  91. ROUABHIA S, Chaabna K
    Hepatitis C infection in eastern Algeria: Between statistics and reality.
    J Med Virol. 2016 Sep 14. doi: 10.1002/jmv.24686.
    PubMed     Text format     Abstract available


    August 2016
  92. HAYES CN, Chayama K
    Interferon stimulated genes and innate immune activation following infection with hepatitis B and C viruses.
    J Med Virol. 2016 Aug 10. doi: 10.1002/jmv.24659.
    PubMed     Text format     Abstract available


    July 2016
  93. REBBANI K, Ababou M, Nadifi S, Kandil M, et al
    Myxovirus resistance 1 gene polymorphisms and outcomes of viral hepatitis B and C infections in Moroccan patients.
    J Med Virol. 2016 Jul 26. doi: 10.1002/jmv.24642.
    PubMed     Text format     Abstract available


    March 2016
  94. AKHTAR A, Khan AH, Sulaiman SA, Soo CT, et al
    HBV and HIV co-infection: Prevalence and clinical outcomes in tertiary care hospital Malaysia.
    J Med Virol. 2016;88:455-60.
    PubMed     Text format     Abstract available


    December 2015
  95. LO G, Sow-Sall A, Diop-Ndiaye H, Mandiouba NC, et al
    Response to comments by Honge et al. on our paper titled "Prevalence of hepatitis B markers in Senegalese HIV-1 infected patients".
    J Med Virol. 2015 Dec 22. doi: 10.1002/jmv.24452.
    PubMed     Text format     Abstract available


  96. HONGE BL, Jespersen S, Medina C, Wejse C, et al
    Comment on Lo et al.: Prevalence of hepatitis B markers in Senegalese HIV-1 infected patients.
    J Med Virol. 2015 Dec 22. doi: 10.1002/jmv.24455.
    PubMed     Text format     Abstract available


    November 2015
  97. DE ARAUJO MARIZ C, Lopes EP, Ximenes RA, Lacerda HR, et al
    Serological markers of hepatitis B and C in patients with HIV/AIDS and active tuberculosis.
    J Med Virol. 2015 Nov 18. doi: 10.1002/jmv.24432.
    PubMed     Text format     Abstract available


    October 2015
  98. FU J, Guo D, Gao D, Huang W, et al
    Clinical analysis of patients suffering from chronic hepatitis B superinfected with other hepadnaviruses.
    J Med Virol. 2015 Oct 28. doi: 10.1002/jmv.24417.
    PubMed     Text format     Abstract available


  99. MOUSSA S, Brah S, Parola P, Gerolami R, et al
    Epidemiological, clinical, virological features of hepatitis B newly diagnosed in 2011 in Marseille University hospitals, southeastern France.
    J Med Virol. 2015 Oct 6. doi: 10.1002/jmv.24398.
    PubMed     Text format     Abstract available


    July 2015
  100. WANG J, Liu S, Cao Y, Yang L, et al
    Prevalence of Kaposi's sarcoma associated herpesvirus among men attending sexually transmitted infections clinics in Anhui, China.
    J Med Virol. 2015 Jul 3. doi: 10.1002/jmv.24321.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis C is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: